Press release
Chemotherapy Induced Febrile Neutropenia Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | BeyondSpring Pharmaceuticals, Enzychem Lifesciences, Tianjin SinoBiotech Lt
Chemotherapy Induced Febrile Neutropenia Pipeline Insights, DelveInsight
Chemotherapy Induced Febrile Neutropenia Overview:
Chemotherapy-Induced Febrile Neutropenia (CIN) is the main dose-limiting side effect in cancer patients undergoing chemotherapy. It can lead to febrile neutropenia (FN) and is linked to higher morbidity and early mortality, increased healthcare costs, and interruptions in potentially life-saving treatments. The occurrence of CIN and its complications, such as fever, infection, and adjustments in chemotherapy doses, varies depending on the type of cancer. A large prospective registry reported CIN rates between 15% and 65% across five major types of cancer: breast, colon, lymphoma, lung, and ovarian. The incidence of FN ranged from 7% to 30%.
Request for a detailed insights report on Chemotherapy Induced Febrile Neutropenia pipeline insights @ https://www.delveinsight.com/report-store/chemotherapy-induced-febrile-neutropenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
"Chemotherapy Induced Febrile Neutropenia Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Chemotherapy Induced Febrile Neutropenia Therapeutics Market.
Key Takeaways from the Chemotherapy Induced Febrile Neutropenia Pipeline Report
DelveInsight's Chemotherapy Induced Febrile Neutropenia pipeline report depicts a robust space with 4+ active players working to develop 4+ pipeline therapies for Chemotherapy Induced Febrile Neutropenia treatment.
Approved in November 2023, Ryzneuta is a long-acting G-CSF indicated for reducing the incidence of infection, as manifested by febrile neutropenia, in adults with non-myeloid malignancies receiving myelosuppressive chemotherapy.
Approved in September 2022, Rolvedon is a novel long-acting G-CSF designed to decrease the incidence of infection, as manifested by febrile neutropenia, in adults undergoing myelosuppressive chemotherapy.
Key Chemotherapy Induced Febrile Neutropenia companies such as BeyondSpring Pharmaceuticals, Enzychem Lifesciences, Tianjin SinoBiotech Ltd., Evive Biotech, and others are evaluating new drugs for Chemotherapy Induced Febrile Neutropenia to improve the treatment landscape.
Promising Chemotherapy Induced Febrile Neutropenia pipeline therapies in various stages of development include Plinabulin, EC-18, and others.
Chemotherapy Induced Febrile Neutropenia Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Chemotherapy Induced Febrile Neutropenia Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chemotherapy Induced Febrile Neutropenia treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Chemotherapy Induced Febrile Neutropenia market.
Download our free sample page report on Chemotherapy Induced Febrile Neutropenia pipeline insights @ https://www.delveinsight.com/sample-request/chemotherapy-induced-febrile-neutropenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Chemotherapy Induced Febrile Neutropenia Emerging Drugs
Plinabulin: BeyondSpring Pharmaceuticals
EC-18: Enzychem Lifesciences
Chemotherapy Induced Febrile Neutropenia Companies
Around four key companies are working on developing therapies for chemotherapy-induced febrile neutropenia. Among them, BeyondSpring Pharmaceuticals has drug candidates for this condition in the most advanced stage, specifically preregistration.
DelveInsight's report covers around 4+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Chemotherapy Induced Febrile Neutropenia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
Chemotherapy Induced Febrile Neutropenia Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Chemotherapy Induced Febrile Neutropenia Therapies and Key Companies: Chemotherapy Induced Febrile Neutropenia Clinical Trials and advancements @ https://www.delveinsight.com/report-store/chemotherapy-induced-febrile-neutropenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Chemotherapy Induced Febrile Neutropenia Pipeline Therapeutic Assessment
• Chemotherapy Induced Febrile Neutropenia Assessment by Product Type
• Chemotherapy Induced Febrile Neutropenia By Stage
• Chemotherapy Induced Febrile Neutropenia Assessment by Route of Administration
• Chemotherapy Induced Febrile Neutropenia Assessment by Molecule Type
Download Chemotherapy Induced Febrile Neutropenia Sample report to know in detail about the Chemotherapy Induced Febrile Neutropenia treatment market @ Chemotherapy Induced Febrile Neutropenia Therapeutic Assessment @ https://www.delveinsight.com/sample-request/chemotherapy-induced-febrile-neutropenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Chemotherapy Induced Febrile Neutropenia Current Treatment Patterns
4. Chemotherapy Induced Febrile Neutropenia - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Chemotherapy Induced Febrile Neutropenia Late-Stage Products (Phase-III)
7. Chemotherapy Induced Febrile Neutropenia Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Chemotherapy Induced Febrile Neutropenia Discontinued Products
13. Chemotherapy Induced Febrile Neutropenia Product Profiles
14. Chemotherapy Induced Febrile Neutropenia Key Companies
15. Chemotherapy Induced Febrile Neutropenia Key Products
16. Dormant and Discontinued Products
17. Chemotherapy Induced Febrile Neutropenia Unmet Needs
18. Chemotherapy Induced Febrile Neutropenia Future Perspectives
19. Chemotherapy Induced Febrile Neutropenia Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Chemotherapy Induced Febrile Neutropenia Pipeline Reports Offerings: https://www.delveinsight.com/report-store/chemotherapy-induced-febrile-neutropenia-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chemotherapy Induced Febrile Neutropenia Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | BeyondSpring Pharmaceuticals, Enzychem Lifesciences, Tianjin SinoBiotech Lt here
News-ID: 3952233 • Views: …
More Releases from DelveInsight Business Research LLP
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Chemotherapy
Chemotherapy Devices Market - Innovation for Life: Chemotherapy Devices Driving …
Newark, New Castle, USA: The "Chemotherapy Devices Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Chemotherapy Devices Market: https://www.growthplusreports.com/report/chemotherapy-devices-market/8623
This latest report researches the industry structure, sales, revenue,…
Chemotherapy Devices Market 2022 Will Boom With Advanced Chemotherapy Technologi …
New Research Study ""Chemotherapy Devices Market 2022 analysis by Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges and Investment Opportunities), Size, Share and Outlook"" has been added to Coherent Market insight
The most recent Global Chemotherapy Devices Market report includes a high-level overview of the industry as well as in-depth analysis of key areas. The overview presented highlights the definition of products and services, as well as their associated applications, at the…
Cancer, chemotherapy and its treatment
Chemotherapy is one of the most commonly used cancer therapies. It employs the use of certain medications to destroy cancer cells or prevent them from spreading to other parts of the body. Chemotherapy may be prescribed alone or in combination with surgery or radiation therapy. Along with chemotherapy, you may also take newer types of cancer-fighting medications.
Chemotherapy can be taken as pills or as injections. You may visit a clinic…
Chemotherapy induced Nausea and Vomiting (CINV) TreatmentS Market Driven by Risi …
According to WHO cancer is one of the most leading causes for death with around 8 million deaths and 14 million new patients in 2012. Chemotherapy, which is received by approximately four million cancer patients each year, is among the most commonly used treatment to fight cancer. However, this mode of treatment has many side effects, an estimate of around 70% - 80% of the patients receiving chemotherapy treatment experience…
Nano Chemotherapy Market Nano Chemotherapy Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Report Table of Contents
Nano Chemotherapeutics Mediations andndash; Solicitation to Nanomedicine
1.1 Overview
1.2 Nano Chemotherapeutics with Pharmaceutical Potential
Significance of Nano Chemotherapeutics to overcome the Chemotherapy Limitations
2.1 Limitations of Conventional Chemotherapy
2.2 Nanotechnology in Cancer Targeting
2.2.1 Active Targeting
2.2.2 Passive Targeting
2.2.3 pH Dependent Drug Delivery Through Nanoparticles
Role…
Nano Chemotherapy Is Emerging As An Important Anti-Cancer Modality By Supplement …
“Global Nano Chemotherapy Market and Clinical Trials Outlook 2022” report highlights the current development in the in the field of nano chemotherapy. Report gives comprehensive insight on various clinical and non-clinical parameters associated with the expansion of global nano chemotherapeutics market. The clinical and pricing insight on chemotherapeutics nanoformulations of approved drugs helps to understand the current market scenario of the nano chemotherapeutics.
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990
Download Report:…
